Home > Boards > US Listed > Biotechs >

Avid Bioservices Inc. (CDMO)

Add CDMO Price Alert      Hide Sticky   Hide Intro
Moderator: TekNuLoof, cjgaddy, north40000, stoneroad, biopharm, 4OurRetirement
Search This Board: 
Last Post: 12/17/2018 11:56:43 AM - Followers: 838 - Board type: Free - Posts Today: 0

Avid Bioservices, Inc. (Nasdaq “CDMO”), Tustin CA. http://www.avidbio.com
Four Avid Fact Sheets a/o 8-9-18: https://avidbio.com/publications/brochures/
Avid Bioservices is a CDMO committed to improving the lives of patients by manufacturing products derived from mammalian cell culture for the biotechnology & biopharmaceutical industries. Services include cGMP clinical & commercial product manufacturing, purification, bulk packaging, stability testing & regulatory strategy, submission, and support. The company also provides a variety of process development activities, including cell line development & optimization, cell culture & feed optimization, analytical methods development, and product characterization.

UPCOMING EVENTS: http://ir.avidbio.com/events-and-presentations
Sep6/4:15-4:40pmET/R.Lias: H.C. Wainwright 20th Annual Global Investment Conf. (NYC) webcast: https://tinyurl.com/y8z5h8ns
Sep10/After: FY'19Q1 (qe 7-31-18) Financials & Conf. Call - CC Transcript: https://tinyurl.com/y8oc6hx8
Sep18/9:55amET/R.Lias: Janney Montgomery Scott 2018 Healthcare Conf. (NYC) webcast: https://tinyurl.com/yb5kp4es
Sep27-28/Booth918: Contract Pharma’s 17th Annual Contracting & Outsourcing Conf.”, NewBWK NJ http://conference.contractpharma.com
Oct4 10amPT: Avid's 2018 Annual Shareholder’s Mtg (Tustin) - Lias' Slideshow/Atendee Report: https://tinyurl.com/yctfzhlb
Dec10/AfterHrs: FY'19Q2 (qe 10-31-18) Financials & Conf. Call Transcript: https://tinyurl.com/y9n374kp

Quotes: Yahoo: Yahoo.com/CDMO Nasdaq: http://www.nasdaq.com/symbol/cdmo RT: http://www.nasdaq.com/symbol/cdmo/real-time
IR: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com, Tim Brons (Media) 415-675-7402 tbrons@vidasp.com

Latest 10K 4-30-18 iss. 7-16-18 https://tinyurl.com/ydc8vew5 PR: https://tinyurl.com/y93fux9h (Cash 4-30-18=$42.3mm)
Latest 10Q 10-31-18 iss. 12-10-18 https://tinyurl.com/y8boxjys PR: https://tinyurl.com/y9yp8b23 (Cash 10-31-18=$32.7mm)
ALL SEC filings for CDMO: https://tinyurl.com/yc4zjyzv
CDMO's Corp. Bylaws (a/o 11-14-14): http://tinyurl.com/y8hsppea - Latest 14A/Proxy: https://tinyurl.com/y7qprpg9 (12-7-17)
Poison Pill adopted 3-16-06: http://tinyurl.com/yvypvh - 44-pg SEC filing: http://tinyurl.com/5m57ut BUNGLER explains in plain language: http://tinyurl.com/mft4nd6

Shares O/S as of 12-3-18=56,067,86 - history since 4-2006: https://tinyurl.com/y9n374kp
...A/O 10-31-18: 3,023,463 stock options outstanding at a wgt.avg. exercise price of $8.22. (pg.16 10Q)
1-12-18: S-3 Shelf Registration filed for up to $125mm https://tinyurl.com/y9qtewpw
...2-20-18: Avid Raises ~$21.8M net, selling 10,294,445@$2.25 (underwriter: Wells Fargo) 8-K: https://tinyurl.com/ya3nenth 424B5: https://tinyurl.com/ycpshgxl
Total INST.+LARGE Holdings now 28,166,076 50.3% (9-30-18) - See https://tinyurl.com/y7vtvdeu

1. Tappan Street (Prasad Phatak): 4,516,107 8.1% (a/o 12-31-17 13G: https://tinyurl.com/yd7xkdzg )
2. Eastern Capital (Kenneth Dart): 4,300,992 7.7% (a/o 12-7-17 14A: https://tinyurl.com/y7qprpg9 acq. 10-2015)
3. Blackrock Inc. (Larry Fink): 3,576,949 6.4% (+315,661 q/e 9-30-18 Nasdaq Inst.)
4. Ronin Trading (John Stafford III+Roger Farley): 2,638,450 4.7% (a/o 4-17-18 13D: https://tinyurl.com/ycf7d2uk )
5. Vanguard Group: 2,330,198 4.2% (+120,673 q/e 9-30-18 Nasdaq Inst.)
6. Snyder Capital: 1,896,878 3.4% (NEW a/o 9-30-18 Nasdaq Inst.)
7. Driehaus Capital: 881,891 1.6% (NEW a/o 9-30-18 Nasdaq Inst.)
Inst. Holdings (Nasdaq) - updated 45-days after each qtr-end: http://www.nasdaq.com/symbol/cdmo/institutional-holdings
INSIDER-Trans: https://tinyurl.com/ycpw4j9z  (formerly PPHM thru 2017: http://tinyurl.com/ypkow8 )
Short Interest, updated twice a month: https://www.nasdaq.com/symbol/cdmo/short-interest
A-T-M (At-The-Market) Sales 3/2009 - 7/14/17 ($272,500,000gr./34,869,747sh=$7.81/sh): http://tinyurl.com/yagmu2on
PPHM shares were 1:7 Reverse Split eff. 7-10-17 (315mm/$.606=>45mm/$4.24) http://tinyurl.com/ycohqn6j
PPHM shares were 1:5 Reverse Split eff. 10-19-09 (~237mm/$.64=>~47.4mm/$3.20) http://tinyurl.com/ykuw588
Potential Value: 9-19-2017: Catalent acquires CDMO Cook Pharmica for $950M ($179Msales x 5.3; EV/EBITDA=17.3) http://tinyurl.com/yd46m8py

AVID TEAM: https://avidbio.com/team - Open Jobs: https://avidbio.applicantpro.com/jobs
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s President and join PPHM’s BOD eff. 9-25-17 https://tinyurl.com/yddufw4s
11-29-17: Tracy L. Kinjerski (ex-CMC Biologics) joins Avid as VP/Bus.Operations https://tinyurl.com/yc4zenkc
2-23-18: CFO Paul Lytle voluntarily resigns eff. 5-24-18 (2-23-18 +90days), "CFO search underway" https://tinyurl.com/ybnjzbv6
5-8-18: Magnus Schroeder (ex-AGC Biologics) joins Avid as VP/Process Sciences https://tinyurl.com/y7tpswaw
5-29-18: Sandra C. Carbonneau (ex-Lonza) joins Avid as Dir./BusDev./EastCoast https://tinyurl.com/ybvrwn2l
7-16-18: Michael Faughnan (ex-Lonza & WuXi Biologics) joins Avid as Sr.Dir./BusDev./West Coast https://tinyurl.com/yaozdggz
7-16-18: Daniel Hart (ex-ENO Holdings) joins Avid as CFO https://tinyurl.com/ychz45p2
Profiles of all 7 BOD members & Compensation as of 11-28-17: https://tinyurl.com/y9lkl4q2
...Joseph Carleone/Chair, Richard Hancock, Gregory Sargen, Joel McComb, Roger Lias, Mark Bamforth, Patrick Walsh

Sept-Nov2017 PPHM/Form4’s for reconstituted 7-person BOD (Options Awarded):
...Joseph Carleone/Chairman, Richard Hancock, Gregory Sargen, Joel McComb: 75,000 @4.67, vesting monthly over 3yrs beg. 12-27-17
...Patrick Walsh: 75,000 @4.08, vesting monthly over 3yrs beg. 11-20-17
...Mark Bamforth: 75,000 @3.88, vesting monthly over 3yrs beg. 11-17-17
...Roger Lias: 150,000 @3.19, vesting in 4 equal annual installments beg. 9-25-18
...Mark Bamforth pur. 50,000@$4.50 on 10-27-17 (open mkt) http://tinyurl.com/ya7pyyu5
...Mark Bamforth pur. 50,000@$2.25 on 2-15-18 (dir. public offering)  https://tinyurl.com/ybsn2gy6
...Joel McComb pur. 50,000@$2.25 on 2-15-18 (dir. public offering) https://tinyurl.com/ybx5saje SOLD 50,000@6.53 on Sept19-20 2018: https://tinyurl.com/y78acunh
...Joseph Carleone pur. 44,445@$2.25 on 2-15-18 (dir. public offering) https://tinyurl.com/ybskshrk
10-24-17: Peregrine Adds Patrick D. Walsh to BOD, "An Industry Veteran with 30+yrs Experience Leading Successful CDMO Org’s” http://tinyurl.com/ydxlv7sb
10-19-17: Peregrine Adds Mark R. Bamforth to BOD, "10yrs/Genzyme; 30yrs of biologics leadership experience, incl. founding 2 CDMOs" http://tinyurl.com/ydxlv7sb

ANALYST COVERAGE: http://ir.avidbio.com/analyst-coverage
Janney Capital - Paul Knight (init. 6-25-18): Buy/PT=$10 https://www.janney.com Coverage: https://jms.bluematrix.com/docs/html/BLUE.html
H.C. Wainwright - Joseph Pantginis (init. 3-24-18) Buy/PT=$11 https://tinyurl.com/ya8hew4c Coverage: https://hcwco.com/services/research
First Analysis Securities - Steven Schwartz & Tracy Marshbanks (init. 3-13-18 https://tinyurl.com/yabgz2ff ): OverWgt/PT=$8
"In transition": Wells Fargo (init. 3-15-18 https://tinyurl.com/yae5bjn5 ): Outperform/PT=$3.50
"In transition": Noble Life Science Partners - Caroline Palomeque https://noblecapitalmarkets.com/life-science (init. 7-16-15); 12-12-17: Buy/PT=$10

12-3-18: CDMO's Revs & Burns By Qtr Table, FY07/Q1 thru FY19/Q2 (fy/e 10-31-18): https://tinyurl.com/y9n374kp
......Avid FY19 (fye 4-30-19) revenues guidance: $51-55mm; committed backlog=$36mm at 10-31-2018.
4-24-18: ”In recent weeks, Avid has signed new agreements with 3 addl. undisclosed intl. drug dev. companies (that’s 4 thus far in CY2018)” https://tinyurl.com/y89whc8d
3-1-18: Acumen Pharm. selects Avid for Process Dev. & Mfg. of ACU193 (Alzheimer’s) https://tinyurl.com/y8jvwleq http://www.acumenpharm.com
2-21-18: Enzyvant selects Avid to commercially mfg. RVT-801 (Farber disease) https://tinyurl.com/yd5xhcx8 http://www.enzyvant.com
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones https://tinyurl.com/yam8gb3h
...NOTE: 2-13-18: Oncologie Licenses Mologen’s immunotherapeutic ‘lefitolimod’ (TLR9 agonist) https://tinyurl.com/y9z54f4x “ONCOLOGIE is backed by top-tier intl. investors and has the objective to dev. novel personalized medicines in the field of immuno-oncology."
2-28-17: Avid & Cook (acq. by Catalent 12-2017 for $950M; $179Msales x 5.3; EV/EBITDA=17.3) remain Halozyme's 2 CMO's (“working to scale-up/validate/qualify Avid II/Myford for Roche collab.”): http://tinyurl.com/h75teta

FACILITIES: https://avidbio.com/services/#state-art-facilities
4-24-18: Avid adding Process Dev. Labs, upgrading capabilities (in phases; total will be >6000sq; 1st one ready Q3CY18/Jul-Sep'18) https://tinyurl.com/y89whc8d
5-2017: Avid II (Myford) adds 2 MilliporeSigma Mobius 2,000L single-use bioreactors; total mfg. capacity now ">11,000L". http://tinyurl.com/ky7bmu4
5-10-17: Halozyme comments on Avid II(Myford) expansion in their 3-31-17/10Q pub. 5-9-17: http://tinyurl.com/mrl34uk
..."validation of the new facility is scheduled to end in Q2/2017… Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20.”
6-2-16: Corp.Update – Avid Expansion & Drug Development - http://tinyurl.com/zvmhqmr
3-7-16/Avid II: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs) http://tinyurl.com/za2j9mt
12-10-15/Avid II: Avid Expansion into MYFORD Facility now GMP-run ready (potential +$40mm sales) - contemplating further expansion http://tinyurl.com/z35623w
12-10-14: Avid to Double Mfg. Capacity(“Myford Expansion”) http://tinyurl.com/mmc3qgy & http://tinyurl.com/kmdgq8t

PRESENTATIONS & ARTICLES: http://ir.avidbio.com/events.cfm
10-25-18/BioPharma: Roger Lias Interview, “Avid expansion to Triple Process Dev. Capacity” https://tinyurl.com/ybtuk29m
9-6-18: H.C. Wainwright 20th Annual Global Investment Conf. (NYC) => Roger Lias' webcast/slideshow: https://tinyurl.com/y8z5h8ns
3-13-18: Roth 30th Annual, Laguna Niguel CA => Roger Lias' webcast/slideshow: https://tinyurl.com/y9keay3u
1-29-18: NobleCon14 - 14th Annual Inv. Conf., Ft.Laud. => Roger Lias' webcast/slideshow https://tinyurl.com/yanwk9yo
1-8-18: EBD's Biotech Showcase 2018 (parallel w/JPM Conf.), SanFran - Roger Lias' slideshow: https://tinyurl.com/ya6tgxxa
11-15-17/Outsourcing-Pharma: “How This R&D Company (Peregrine) is Transitioning to a Pure-Play CDMO: ‘Opportunities Are Almost Endless’" - Recap of interviews with Steve King & Avid Pres. Roger Lias http://tinyurl.com/y7dv9faz

12-3-18: Qtly. Conf. Call (Lias/Hart//Kinjerski) PR & Transcript https://tinyurl.com/y9n374kp
10-4-18: ASM/2018 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Report https://tinyurl.com/yctfzhlb
9-10-18: Qtly. Conf. Call (Lias/Hart) PR & Transcript https://tinyurl.com/y8oc6hx8
...Roger Lias, "During the qtr, we advanced the projects of our existing active clients and continue to engage with numerous potential new customers."
7-16-18: Qtly. Conf. Call (Lias/Kinjerski) PR & Transcript https://tinyurl.com/yaozdggz
...Roger Lias, “In a short period, we’ve established a targeted business dev. operation that is actively providing visibility for Avid Bioservices within our fast growing but competitive marketplace.”
3-12-18: Qtly. Conf. Call (Lias/Kinjerski/Lytle) PR & Transcript https://tinyurl.com/yakdl4wj
...Roger Lias, ”I'm pleased to be able to report that in a very short period of time we've generated significant interest from both emerging & growth biopharmaceutical players and from pharmaceutical multinationals. I'm confident that the plan we're executing will drive a considerable increase in backlog and the opportunity to further enhance capacity utilization in the future.”
......From the 3-12-18 PR: “At present, we are in late-stage negotiations with several potential new customers and expect to announce the executed agreements before the end of the FY[4-30-18].”
1-18-18: ASM/2017 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Reports https://tinyurl.com/yca6enbr 12-7-17 PROXY/14A: https://tinyurl.com/y7qprpg9
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6
...Roger Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
9-11-17: Qtly. Conf. Call (King/Lias/Lytle) Transcript http://tinyurl.com/y9y8qdac
...Steve King: “For this reason, we have concluded that in order to best position Peregrine’s R&D assets for successful development, they should be advanced by a partner with the appropriate expertise and ample resources to invest in the necessary clinical trials. To that end, we have been working diligently towards the transformation of the overall business to becoming a pure-play CDMO, while assessing the best strategic options for the R&D assets that would allow stockholders to directly see the future value from their continued developments. By partnering & eliminating future R&D expenditures, we believe we are best positioning Avid for future growth. Through reinvestment & expansion, we believe we will attract new customers and extend current contracts that will help position Avid as a leading U.S. CDMO. We are moving forward expeditiously with strategic discussions as we recognize the need to move quickly both from the R&D & CDMO standpoints. We hope to bring this process to completion over the coming months and will update you on our progress.”
7-14-17: Qtly. Conf. Call (King/Shan/Lytle) Transcript http://tinyurl.com/yb4wulvu
...Steve King: “We are seriously considering the possibility of separating our 2 distinct businesses, Avid and R&D/PS-Targeting.”
3-13-17: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/grhwjvy
...Steve King: “We believe the recent improvement of stock price is a growing recognition of the value of Avid, and having the full value of the Avid business reflected in our stock price is a top priority.”
12-12-16: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/hhn4gga
...Steve King: “Our goal is to bring the overall company to profitability within the next 18mos. We believe just the value of Avid Bioservices is far greater than our current market cap and is only growing in value."
10-13-16 ASM/2016: ATTENDEE Reports & Link to CEO Steve King's 35min/45slide webcast: http://tinyurl.com/jx7ouay

Feb. 2018: Peregrine Pharmaceuticals completed its Mid’17-Early’18 Transition to a Pure-Play CDMO
(Contract Development & Manufacturing Organization), Avid Bioservices, Inc. - CEO: Roger Lias.

**FULL PPHM=>CDMO Transition History (Ronin/SWIM): https://tinyurl.com/ybqvzwhg
1-8-17: Peregrine chgs. name to “Avid Bioservices, Inc.”; new ticker: “CDMO” (+CDMOP) https://tinyurl.com/y8vhjow4
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones https://tinyurl.com/yam8gb3h
...12-13-18/8-K: Overview of Oncologie sale: https://tinyurl.com/yab9c6cr
NOTE: “PS-targeting Exosome tech. not included; back to UTSW", see: https://tinyurl.com/yakdl4wj

Click here for an ARCHIVE of the History of Peregrine’s Anti-PS/Bavituximab Platform - MOA, Trials, and Activity over the years, from early 2000’s thru 2017, prior to being Sold to ONCOLOGIE:
Of Interest (post Oncologie Sale):
4-20-18/AACR’18: MSKCC(LudwigCC) Tweets about 2 WolchokLAB/”PPHM” Anti-PS Posters https://tinyurl.com/ycgjhvqa
4-26-18: New Bavi+Keytruda/LIVER Ph2 IST Trial, Sponsor=UTSW, Collab=MERCK https://tinyurl.com/y7fd9vdb
6-7-18: Oncologie Obtains $16.5M Seed Funding Led by Pivotal bioVenture Partners China Fund https://tinyurl.com/ybrrbgg7
6-7-18/BioCentury: Laura Benjamin states, “Oncologie plans to begin a trial mid-summer '18 evaluating Bavi to treat HCC and a P-O-C trial in Gastric cancer in 1Q19/2Q19.” https://tinyurl.com/ycb8r7sm
12-3-18: During q/e 10-31-18, Avid sold remaining legacy R&D asset, r84(anti-VEGF), to Oncologie for $1.0M upfront. Avid is eligible to receive up to an addl. $21M in dev/reg./comm. milestones, and low to mid-single digit royalties on net sales upon commercialization of products utilizing r84 https://tinyurl.com/y9n374kp

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CDMO News: Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2019 and Recent Developments 12/10/2018 04:05:00 PM
CDMO News: Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 12/05/2018 04:05:00 PM
CDMO News: Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2019 After Market Close on December 10, 2018 12/03/2018 08:05:00 AM
CDMO News: Avid Bioservices to Exhibit at the 17th Annual Contracting & Outsourcing Conference 09/20/2018 08:05:00 AM
CDMO News: Avid Bioservices Reports Financial Results for First Quarter Fiscal 2019 and Recent Developments 09/10/2018 04:05:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#329340  Sticky Note 12-10-18 Qtly CC-Transcript, PR(Q2FY19/qe10-31-18), Avid Revs History Table cjgaddy 12/11/18 03:48:17 PM
#329252  Sticky Note 10-4-18/2018 ASM: Roger Lias’ Slideshow & Attendee Report cjgaddy 11/20/18 01:57:23 PM
#329238  Sticky Note Total INST.+LARGE Holdings now 28,166,076 50.3% (9-30-18) cjgaddy 11/16/18 08:48:38 AM
#324889  Sticky Note ARCHIVE of Peregrine’s Anti-PS/Bavituximab Platform - MOA, Trials, cjgaddy 02/17/18 08:45:37 AM
#324848  Sticky Note 2-12-18: Avid Sells PS/IP to Oncologie; CDMO-Transition History cjgaddy 02/16/18 09:24:50 AM
#294957  Sticky Note PPHM/MSKCC(Jedd Wolchok Lab) Collab: #1/Bavi+PD1+Rad, #2/Bavi+”ACT” cjgaddy 04/14/17 10:05:54 AM
#329348   I think somewhat predictable trading pattern. Those bfiest 12/17/18 11:56:43 AM
#329346   Strange trading pattern with this stock....seems to be westjtter 12/14/18 03:05:37 PM
#329345   I issued a BUY!!! on November 20th at $4.82.......... ElSid18 12/13/18 09:45:08 AM
#329344   Yes, surprising after yesterday’s action. I bought cheynew 12/12/18 10:50:49 AM
#329343   Dec $5 options starting to look pretty good. The Other Guy 12/12/18 10:47:21 AM
#329341   First Analysis reiterated their buy with $8 price target cheynew 12/11/18 04:07:32 PM
#329340   12-10-18 Qtly CC-Transcript, PR(Q2FY19/qe10-31-18), Avid Revs History Table cjgaddy 12/11/18 03:48:17 PM
#329339   Lias stated on the last cc that they jakedogman1 12/11/18 02:28:05 PM
#329338   FWIW, I thought the results were decent and westjtter 12/11/18 02:01:13 PM
#329337   Given overall market and lack of foreseeable catalysts, stoneroad 12/11/18 11:10:50 AM
#329336   Do you think this will go lower? cheynew 12/11/18 11:00:52 AM
#329335   “They never promised profitability this year.” Well, actually... Steve The Other Guy 12/11/18 10:44:21 AM
#329334   Thems were the days! wxcbs 12/11/18 10:41:40 AM
#329333   Ha, I go back to 1998 and TCLN. wxcbs 12/11/18 10:40:13 AM
#329332   The company is doing what they said they corporalagarn 12/11/18 10:34:49 AM
#329331   Coulda, Woulda, Shoulda...........Man, I wish I'd have never drontle2 12/11/18 10:26:01 AM
#329330   Hate to say it, but dead money for stoneroad 12/11/18 10:01:06 AM
#329329   Who would be. Nothing new. Same old BS. vieuxcarre 12/11/18 09:45:39 AM
#329328   Market not impressed. IMO Pd purpledawgs 12/11/18 09:44:14 AM
#329327   Guide to Owning PPHM/CDMO Through the Years patientlywaiting 12/11/18 08:18:26 AM
#329326   In a report released today, Joseph Pantginis from cheynew 12/11/18 07:21:47 AM
#329325   as well as low to mid-single digit royalties tech0200 12/10/18 08:34:52 PM
#329324   agree... and halo's biz could get big and jakedogman1 12/10/18 07:10:14 PM
#329323   I thought the call was positive. It bfiest 12/10/18 06:43:59 PM
#329322   At least Lias said he would announce contracts. cheynew 12/10/18 05:56:58 PM
#329321   We go sideways until some contracts are signed djohn 12/10/18 05:55:46 PM
#329320   I thought one of us in attendance at eb0783 12/10/18 05:24:41 PM
#329319   Up .24 AH on low 400+ shares. cheynew 12/10/18 05:04:25 PM
#329318   CDMO IS KILLING IT WOOHOO GLAD I’M OUT FRAUDSTERS vieuxcarre 12/10/18 04:47:03 PM
#329317   -- Fiscal 2019 Projected Revenue of $51 to goodplenty100 12/10/18 04:30:53 PM
#329316   Recent Developments goodplenty100 12/10/18 04:28:20 PM
#329315   Not one after hours trade on the news. DrRocker 12/10/18 04:17:56 PM
#329314   Sadly, rather disappointing. Turnaround seems to be dragging. stoneroad 12/10/18 04:12:53 PM
#329312   I am thinking that person is looking for asmarterwookie 12/10/18 01:53:29 PM
#329311   242 Dec $5 calls traded. cheynew 12/10/18 01:39:14 PM
#329310   ConferenceCall Link: https://edge.media-server.com/m6/p/5gs2g7b5 glta,eom. 4OurRetirement 12/10/18 12:48:48 PM
#329309   Thanks Chey! That may just be enough for asmarterwookie 12/10/18 12:36:12 PM
#329308   140 Jan 7.50 traded today at the ask. cheynew 12/10/18 12:27:50 PM
#329307   I am expecting an earnings beat. I JCNJ 12/10/18 12:25:45 PM
#329306   LOL PD. asmarterwookie 12/10/18 12:20:41 PM
#329305   Just noticed options sizzle is up to 8.222 asmarterwookie 12/10/18 12:16:49 PM
#329304   I am expecting a miss. That way purpledawgs 12/10/18 12:16:32 PM
#329303   ...and we have no clue on whether they asmarterwookie 12/10/18 11:58:40 AM
#329302   Conference call at 4:30 today. cheynew 12/10/18 11:32:38 AM
#329301   Indeed. Amen. This entire board is a fraud vieuxcarre 12/10/18 11:24:32 AM
#329300   The payoff money to Jedd Wolchok to patientlywaiting 12/10/18 11:23:24 AM
#329297   Jedd Wolchok probably saw the disaster-in-the-making of Johnson/Swartz/Pohl/King The Other Guy 12/10/18 10:31:32 AM
#329295   No. But I did learn about medical Mary jane. asmarterwookie 12/10/18 09:02:00 AM
#329294   Did anyone find out the real reason why biopharm 12/10/18 08:43:12 AM